MORE Savings Act
Sponsored By: Representative Dean, Madeleine [D-PA-4]
Introduced
Summary
Eliminate patient cost-sharing for evidence‑based opioid use disorder (OUD) treatment and recovery services across Medicare, private plans, and Medicaid. This bill would remove coinsurance, copayments, and deductibles for OUD medications, behavioral health care, and community recovery supports to make treatment more affordable and accessible.
Show full summary
- People with OUD and their families would get no cost-sharing for prescription drugs to treat OUD or reverse overdose, behavioral health services, and recovery supports under private plans for plan years beginning on or after January 1, 2027.
- Medicare beneficiaries in up to 15 states would be covered by a CMS Innovation Center demonstration that eliminates cost-sharing for specified OUD drugs, non-hospital residential treatment, and community recovery services.
- States could claim a temporary 90% federal Medicaid match for medication-assisted treatment (MAT) and may opt to include peer counseling and transportation as funded recovery supports.
Personalized for You
How does this bill affect your finances?
Personalize government policy and PRIA will tell you what this bill means for your household, plus every other piece of legislation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Bill Overview
Analyzed Economic Effects
3 provisions identified: 3 benefits, 0 costs, 0 mixed.
Higher Medicaid match for addiction treatment
If enacted, the federal government would pay 90 percent of qualifying Medicaid costs for medication-assisted treatment during the covered period that begins on the date of enactment. The rule would apply to the 50 States and the District of Columbia. The bill would also let each State choose to include recovery support services, like peer counseling and transportation, as part of Medicaid MAT coverage. States that add these services could expand what Medicaid pays for when provided with MAT drugs.
No-cost opioid care for Medicare
If enacted, the bill would direct the Medicare innovation center to run a model that removes copays, coinsurance, and deductibles for certain opioid treatments. The model would cover OUD drugs and overdose-reversal drugs, behavioral health and recovery supports, and licensed non-hospital residential OUD treatment. The government would pick 15 States with high Medicare populations, high opioid death rates, and large rural shares. The model must begin within six months of enactment and would be protected from termination or modification rules for the first five years after it starts.
No-cost opioid treatment in private plans
If enacted, group health plans and individual market issuers would have to cover certain opioid treatments with no copays, coinsurance, or deductibles starting in plan years that begin on or after January 1, 2027. Covered items would include prescription drugs to treat OUD or reverse overdose, behavioral health services for OUD (including licensed non-hospital residential treatment), and recovery supports given with medication-assisted treatment like peer counseling and transportation. The rule would apply to ERISA-covered group plans and plans addressed in the tax code as written in the bill.
Sponsors & CoSponsors
Sponsor
Dean, Madeleine [D-PA-4]
PA • D
Cosponsors
There are no cosponsors for this bill.
Roll Call Votes
No roll call votes available for this bill.
View on Congress.gov